ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that Peter Ho, PhD, Director of Business Development, will present a company overview at 2:00 pm ET and participate in a panel discussion on advances in immunotherapy for glioma at 2:45 pm ET at the 3
Annual Cancer Immunotherapy: A Long-Awaited Reality conference on Thursday, October 4, 2012, at the New York Academy of Medicine.
A live and archived webcast of the company's presentation at the conference hosted by MD Becker Partners LLC will be available at
John S. Yu, MD, Interim Chief Executive Officer, will present a corporate overview and business update at the 11
Annual BIO Investor Forum on October 10, 2012 at 3:00 pm PT at the Palace Hotel, San Francisco, CA.
To access the live audio webcast of the BIO Investor Forum presentation, please log on through a link located in the Investor Relations section of ImmunoCellular's website at
, under the Investors, Webcasts & Presentations tab. A replay of the webcasts will be available one hour after the conclusion of the live events.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. To learn more about ImmunoCellular, please visit